Page last updated: 2024-11-13

surotomycin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID46700778
SCHEMBL ID17284900
MeSH IDM000609696

Synonyms (15)

Synonym
cb-183,315
cb-315 ,
surotomycin
cb-183315
surotomycin (usan/inn)
D10380
cb 183315
on0n776n05 ,
surotomycin [usan:inn]
unii-on0n776n05
1233389-51-9
surotomycin [inn]
surotomycin [usan]
SCHEMBL17284900
DTXSID60153980

Research Excerpts

Overview

Surotomycin (CB-183,315) is an orally administered, minimally absorbed, selective bactericidal cyclic lipopeptide. It is in phase 3 development for the treatment of Clostridium difficile-associated diarrhea.

ExcerptReferenceRelevance
"Surotomycin (CB-183,315) is an orally administered, minimally absorbed, selective bactericidal cyclic lipopeptide in phase 3 development for the treatment of Clostridium difficile-associated diarrhea. "( Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium.
Chesnel, L; Mascio, CT; Silverman, JA; Thorne, G, 2014
)
3.29
"Surotomycin is a rapidly bactericidal cyclic lipopeptide antibiotic that is in clinical trials for CDI treatment and that has demonstrated superiority over vancomycin in preventing CDI relapse."( Mutations associated with reduced surotomycin susceptibility in Clostridium difficile and Enterococcus species.
Adams, HM; Chesnel, L; Li, X; Mascio, C; Palmer, KL, 2015
)
1.42
"Surotomycin is a bactericidal cyclic lipopeptide in development for treatment ofClostridium difficile-associated diarrhea that has selective and potent activity againstC."( Impact of Surotomycin on the Gut Microbiota of Healthy Volunteers in a Phase 1 Clinical Trial.
Chesnel, L; Citron, DM; Dale, SE; Goldstein, EJ; Tyrrell, KL, 2016
)
1.56
"Surotomycin is a cyclic lipopeptide in development for Clostridium difficile-associated diarrhea. "( Evaluating the Effects of Surotomycin Treatment on Clostridium difficile Toxin A and B Production, Immune Response, and Morphological Changes.
Alam, MJ; Bassères, E; Chesnel, L; Endres, BT; Garey, KW; Khaleduzzaman, M, 2016
)
2.18
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's22 (95.65)24.3611
2020's1 (4.35)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.76 (24.57)
Research Supply Index3.33 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (17.39%)5.53%
Reviews5 (21.74%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (60.87%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]